Belite Bio (BLTE) Competitors $62.97 +0.01 (+0.02%) (As of 10:26 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends BLTE vs. JAZZ, MDGL, LEGN, NUVL, IONS, BPMC, ELAN, CYTK, CORT, and TGTXShould you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Jazz Pharmaceuticals (JAZZ), Madrigal Pharmaceuticals (MDGL), Legend Biotech (LEGN), Nuvalent (NUVL), Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Corcept Therapeutics (CORT), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical preparations" industry. Belite Bio vs. Jazz Pharmaceuticals Madrigal Pharmaceuticals Legend Biotech Nuvalent Ionis Pharmaceuticals Blueprint Medicines Elanco Animal Health Cytokinetics Corcept Therapeutics TG Therapeutics Belite Bio (NASDAQ:BLTE) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment. Do insiders & institutionals believe in BLTE or JAZZ? 0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 4.2% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate BLTE or JAZZ? Belite Bio presently has a consensus target price of $89.00, indicating a potential upside of 41.34%. Jazz Pharmaceuticals has a consensus target price of $177.00, indicating a potential upside of 47.38%. Given Jazz Pharmaceuticals' higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Belite Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Belite Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Jazz Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87 Does the MarketBeat Community prefer BLTE or JAZZ? Jazz Pharmaceuticals received 1095 more outperform votes than Belite Bio when rated by MarketBeat users. However, 96.77% of users gave Belite Bio an outperform vote while only 80.76% of users gave Jazz Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBelite BioOutperform Votes3096.77% Underperform Votes13.23%Jazz PharmaceuticalsOutperform Votes112580.76% Underperform Votes26819.24% Which has more risk & volatility, BLTE or JAZZ? Belite Bio has a beta of -1.64, meaning that its stock price is 264% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Which has stronger valuation and earnings, BLTE or JAZZ? Jazz Pharmaceuticals has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBelite BioN/AN/A-$31.63M-$1.11-56.73Jazz Pharmaceuticals$3.99B1.82$414.83M$7.1016.92 Does the media refer more to BLTE or JAZZ? In the previous week, Jazz Pharmaceuticals had 19 more articles in the media than Belite Bio. MarketBeat recorded 19 mentions for Jazz Pharmaceuticals and 0 mentions for Belite Bio. Jazz Pharmaceuticals' average media sentiment score of 0.42 beat Belite Bio's score of -0.55 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Belite Bio Negative Jazz Pharmaceuticals Neutral Is BLTE or JAZZ more profitable? Jazz Pharmaceuticals has a net margin of 11.60% compared to Belite Bio's net margin of 0.00%. Jazz Pharmaceuticals' return on equity of 29.30% beat Belite Bio's return on equity.Company Net Margins Return on Equity Return on Assets Belite BioN/A -31.94% -30.73% Jazz Pharmaceuticals 11.60%29.30%9.72% SummaryJazz Pharmaceuticals beats Belite Bio on 14 of the 17 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLTE vs. The Competition Export to ExcelMetricBelite BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.93B$6.72B$5.03B$9.00BDividend YieldN/A3.07%4.81%4.06%P/E Ratio-56.7310.57135.3217.11Price / SalesN/A192.491,131.52121.09Price / CashN/A57.1640.5137.93Price / Book19.205.134.724.77Net Income-$31.63M$152.09M$118.53M$225.20M7 Day Performance-0.63%-3.41%12.95%-1.49%1 Month Performance-23.52%-2.98%10.81%4.51%1 Year Performance40.24%10.62%30.85%17.92% Belite Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLTEBelite Bio2.4213 of 5 stars$62.97+0.0%$89.00+41.3%+40.3%$1.93BN/A-56.7320JAZZJazz Pharmaceuticals4.8479 of 5 stars$125.01+1.6%$177.00+41.6%+0.5%$7.56B$3.99B17.332,800MDGLMadrigal Pharmaceuticals4.2469 of 5 stars$309.23+1.6%$347.33+12.3%+27.3%$6.74BN/A-12.1490Positive NewsLEGNLegend Biotech1.6886 of 5 stars$33.72-4.0%$81.54+141.8%-45.3%$6.16B$520.18M-36.971,800NUVLNuvalent2.3073 of 5 stars$86.63-0.3%$112.60+30.0%+10.6%$6.16BN/A-25.0340Insider TradePositive NewsIONSIonis Pharmaceuticals4.4117 of 5 stars$38.53+5.2%$60.65+57.4%-28.5%$6.08B$803.07M-15.00800Short Interest ↓Positive NewsBPMCBlueprint Medicines2.876 of 5 stars$95.54+2.5%$122.11+27.8%+4.8%$6.07B$249.38M-44.17640Insider TradeELANElanco Animal Health3.8088 of 5 stars$12.17+0.6%$16.75+37.6%-14.1%$6.02B$4.45B30.259,300CYTKCytokinetics4.0192 of 5 stars$49.20+1.1%$83.93+70.6%+28.5%$5.81B$3.22M-9.04250Analyst ForecastCORTCorcept Therapeutics4.6154 of 5 stars$54.70-1.3%$65.25+19.3%+71.6%$5.73B$482.38M43.97300Short Interest ↓TGTXTG Therapeutics4.2991 of 5 stars$34.75+8.5%$40.67+17.0%+70.8%$5.41B$233.66M-320.17290Positive News Related Companies and Tools Related Companies JAZZ Alternatives MDGL Alternatives LEGN Alternatives NUVL Alternatives IONS Alternatives BPMC Alternatives ELAN Alternatives CYTK Alternatives CORT Alternatives TGTX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BLTE) was last updated on 12/19/2024 by MarketBeat.com Staff From Our PartnersTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLTE Stock Alerts